Increased dosage of DYRK1A and DSCR1 delays neuronal differentiation in neocortical progenitor cells

Genes and Development

Volumn 27, Issue 24, 2013, Pages 2708-2721

  Kurabayashi, Nobuhiro ^a   Sanada, Kamon ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Developing neocortex; Down's syndrome; Neural progenitor; Neurogenesis

Indexed keywords

CALCINEURIN; DOWN SYNDROME CRITICAL REGION 1; DUAL SPECIFICITY TYROSINE PHOSPHORYLATED AND REGULATED KINASE 1A; PROTEIN SERINE THREONINE KINASE; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE S PHASE; CELL FATE; CHROMOSOME 21; CONTROLLED STUDY; DOWN SYNDROME; EMBRYO; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; IMMUNOFLUORESCENCE; IN SITU HYBRIDIZATION; MENTAL DEFICIENCY; MOUSE; NEOCORTEX; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; STEM CELL;

DEVELOPING NEOCORTEX; DOWN'S SYNDROME; NEURAL PROGENITOR; NEUROGENESIS;

ANIMALS; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; DOWN SYNDROME; GENE DOSAGE; GENE EXPRESSION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MUSCLE PROTEINS; NEOCORTEX; NEUROGENESIS; NFATC TRANSCRIPTION FACTORS; PLASMIDS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; STEM CELLS;

EID: 84890673043     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.226381.113     Document Type: Article

References (51)

1. Amano K., Sago H, Uchikawa C, Suzuki T, Kotliarova SE, Nukina N, Epstein CJ, Yamakawa K. 2004. Dosage-dependent overexpression of genes in the trisomic region of Ts1Cje mouse model for Down syndrome. Hum Mol Genet 13: 1333-1340.
2. Antonarakis S. E, Lyle R, Dermitzakis ET, Reymond A, Deutsch S. 2004. Chromosome 21 and Down syndrome: From genomics to pathophysiology. Nat Rev Genet 5: 725-738.
3. Arron J. R, Winslow MM, Polleri A, Chang CP, Wu H, Gao X, Neilson J. R, Chen L, Heit JJ, Kim SK, et al. 2006. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 441: 595-600.
4. Asada N., Sanada K, Fukada Y. 2007. LKB1 regulates neuronal migration and neuronal differentiation in the developing neocortex through centrosomal positioning. J Neurosci 27: 11769-11775.
5. Bulfone A., Smiga SM, Shimamura K, Peterson A, Puelles L, Rubenstein J.L. 1995. T-brain-1a homolog of Brachyury whose expression defines molecularly distinct domains within the cerebral cortex. Neuron 15: 63-78.
6. Canfield M. A, Honein MA, Yuskivm N, Xing J, Mai CT, Collins JS, Devine O, Petrini J, Ramadhani TA, Hobbs CA, et al. 2006. National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001. Birth Defects Res A Clin Mol Teratol 76: 747-756.
7. Chakrabarti L., Galdzicki Z, Haydar TF. 2007. Defects in embryonic neurogenesis and initial synapse formation in the forebrain of the Ts65Dn mouse model of Down syndrome. J Neurosci 27: 11483-11495.
8. Chang C. P, Neilson JR, Bayle JH, Gestwicki JE, Kuo A, Stankunas K, Graef IA, Crabtree GR. 2004. A field of myocardial-endocardial NFATsignaling underlies heart valve morphogenesis. Cell 118: 649-663.
9. Chapman R. S, Hesketh LJ. 2000. Behavioral phenotype of individuals with Down syndrome. Ment Retard Dev Disabil Res Rev 6: 84-95.
10. Chenn A., Walsh CA. 2002. Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. Science 297: 365-369.
11. Chow C. W, Rincon M, Davis RJ. 1999. Requirement for transcription factor NFAT in Interleukin-2 expression. Mol Cell Biol 19: 2300-2307.
12. 2+, calcineurin, and NF-AT. Cell 96: 611-614.
13. Delabar J. M, Theophile D, Rahmani Z, Chettouh Z, Blouin JL, Prieur M., Noel B, Sinet PM. 1993. Molecular mapping of twenty-four features of Down syndrome on chromosome 21. Eur J Hum Genet 1: 114-124.
14. Dominguez M. H, Ayoub AE, Rakic P. 2013. POU-III transcription factors (Brn1, Brn2, and Oct6) influence neurogenesis, molecular identity, and migratory destination of upper-layer cells of the cerebral cortex. Cereb Cortex 23: 2632-2643.
15. Fotaki V., Dierssen M, Alcantara S, Martine S, Marti E, Casas C, Visa J., Soriano E, Estivill X, Arbonés ML. 2002. Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. Mol Cell Biol 22: 6636-6647.
16. Fuentes J. J, Genesca L, Kingsbury TJ, Cunningham KW, Pérez-Riba M., Estivill X, de la Luna S. 2000. DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. Hum Mol Genet 9: 1681-1690.
17. Golden J. A, Hyman B. 1994. Development of the superior temporal neocortex is anomalous in trisomy 21. J Neuropathol Exp Neurol 53: 513-520.
18. Götz M, Stoykova A, Gruss P. 1998. Pax6 controls radial glia differentiation in the cerebral cortex. Neuron 21: 1031-1044.
19. Graef I. A, Mermelstein PG, Stankunas K, Neilson JR, Deisseroth K, Tsien RW, Crabtree GR. 1999. L-type calcium channels and GSK-3 regulate the activity of NF-ATc4 in hippocampal neurons. Nature 401: 703-708.
20. 2+/calcineurin and NFATc3/c4 pattern the developing vasculature. Cell 105: 863-875.
21. Guedj F., Pereira PL, Najas S, Barallobre MJ, Chabert C, Souchet B, Sebrie C, Verney C, Herault Y, Arbones M, et al. 2012. DYRK1A: A master regulatory protein controlling brain growth. Neurobiol Dis 46: 190-203.
22. Guimera J., Casas C, Estivill X, Pritchard M. 1999. Human minibrain homologue (MNBH/DYRK1): Characterization, alternative splicing, differential tissue expression, and overexpression in Down syndrome. Genomics 57: 407-418.
23. Gwack Y., Sharma S, Nardone J, Tanasa B, Iuga A, Srikanth S, Okamura H., Bolton D, Feske S, Hogan PG, et al. 2006. A genome-wide Drosophila RNAi screen identifies DYRKfamily kinase as regulators of NFAT. Nature 441: 646-650.
24. Hämmerle B, Elizalde C, Tejedor FJ. 2008. The spatio-temporal and subcellular expression of the candidate Down syndrome gene Mnb/Dyrk1A in the developing mouse brain suggests distinct sequential roles in neuronal development. Eur J Neurosci 27: 1061-1074.
25. Hasle H., Clemmensen IH, Mikkelsen M. 2000. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 355: 165-169.
26. Ishihara K., Amano K, Takaki E, Shimohata A, Sago H, Epstein CJ, Yamakawa K. 2010. Enlarged brain ventricles and impaired neurogenesis in the Ts1Cje and Ts2Cje mouse models of Down syndrome. Cereb Cortex 20: 1131-1143.
27. Korenberg J. R, Kawashima H, Pulst SM, Ikeuchi T, Ogasawara N, Yamamoto K., Schonberg SA, West R, Allen L, Magenis E, et al. 1990. Molecular definition of a region of chromosome 21 that causes features of the Down syndrome phenotype. Am J Hum Genet 47: 236-246.
28. Lu J., Esposito G, Scuderi C, Steardo L, Delli-Bovi LC, Hecht JL, Dickinson BC, Chang CJ, Mori T, Sheen V. 2011. S100B and APP promote a gliocentric shift and impaired neurogenesis in Down syndrome neural progenitors. PLoS ONE 6: e22126.
29. Mann D. MA, Yates PO, Marcyniuk B, Ravindra CR. 1987. Loss of neurons from cortical and subcortical areas in Down's syndrome patients at middle age: Quantitative comparisons with younger Down's patients and patients with Alzheimer's disease. J Neurol Sci 80: 79-89.
30. McCormick MK, Schinzel A, Petersen MB, Stetten G, Driscoll DJ, Cantu ES, Tranebjaerg L, Mikkelsen M, Watkins PC, Antonarakis S.E. 1989. Molecular genetic approach to the characterization of the 'Down syndrome region' of chromosome 21. Genomics 5: 325-331.
31. Moldrich R. X, Dauphinot L, Laffaire J, Vitalis T, Hérault Y, Beart P. M, Rossier J, Vivien D, Gehrig C, Antonarakis SE, et al. 2009. Proliferation deficits and gene expression dysregulation in Down's syndrome (Ts1Cje) neural progenitor cells cultured from neurospheres. J Neurosci Res 87: 3143-3152.
32. Molkentin J. D, Lu JR, Antosm CL, Markham B, Richardsonm J, Robbins J., Grant SR, Olson EN. 1998. Calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93: 215-228.
33. Müller MR, Rao A. 2010. NFAT, immunity and cancer: A transcription factor comes of age. Nat Rev Immunol 10: 645-656.
34. Nieto M., Monuki ES, Tang H, Imitola J, Haubst N, Khoury SJ, Cunningham J., Götz M, Walsh CA. 2004. Expression of Cux-1 and Cux-2 in the subventricular zone and upper layers II-IV of the cerebral cortex. J Comp Neurol 479: 168-180.
35. Olson L. E, Richtsmeier JT, Leszl J, Reeves RH. 2004. A chromosome 21 critical region does not cause specific Down syndrome phenotypes. Science 306: 687-690.
36. Olson L. E, Roper RJ, Sengstaken CL, Peterson EA, Aquino V, Galdzicki Z., Siarey R, Pletnikov M, Moran TH, Reeves RH. 2007. Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice. Hum Mol Genet 16: 774-782.
37. Petit T. L, LeBoutillier JC, Alfano DP, Becker LE. 1984. Synaptic development in the human fetus: A morphometric analysis of normal and Down's syndrome neocortex. Exp Neurol 83: 13-23.
38. Roizen N. J, Patterson D. 2003. Down's syndrome. Lancet 361: 1281-1289.
39. Rothermel B., Vega RB, Yang J, Wu H, Bassel-Duby R, Williams RS. 2000. A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling. J Biol Chem 275: 8719-8725.
40. Ryeom S., Baek KH, Rioth MJ, Lynch RC, Zaslavsky A, Birsner A, Yoon SS, McKeon F. 2008. Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth. Cancer Cell 13: 420-431.
41. Sago H., Carlson EJ, Smith DJ, Kilbridge J, Rubin EM, Mobley WC, Epstein CJ, Huang TT. 1998. Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities. Proc Natl Acad Sci 95: 6256-6261.
42. Sanada K., Tsai LH. 2005. G protein βγ subunits and AGS3 control spindle orientation and asymmetric cell fate of cerebral cortical progenitors. Cell 122: 119-131.
43. Schmidt-Sidor B., Wisniewski KE, Shepard TH, Sersen EA. 1990. Brain growth in Down syndrome subjects 15 to 22 weeks of gestational age and birth to 60 months. Clin Neuropathol 9: 181-190.
44. Sui G., Soohoo C, Affar EB, Gay F, Shi Y, Forrester WC, Shi Y. 2002. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci 99: 5515-5520.
45. Takashima S., Becker LE, Armstrong DL, Chan F. 1981. Abnormal neuronal development in the visual cortex of the human fetus and infant with Down's syndrome. A quantitative and qualitative golgi study. Brain Res 225: 1-21.
46. Tanzi R.E. 1996. Neuropathology in the Down's syndrome brain. Nat Med 2: 31-32.
47. Tuan N., Simone DG. 2008. NFAT signaling in neural development and axon growth. Int J Dev Neurosci 26: 141-145.
48. van Rooij E., Doevendans PA, de Theije CC, Babiker FA, Molkentin J. D, de Windt LJ. 2002. Requirement of nuclear factor of activated T-cells in calcineurin-mediated cardiomyocyte hypertrophy. J Biol Chem 277: 48617-48626.
49. Weitzdoerfer R., Dierssen M, Fountoulakis M, Lubec G. 2001. Fetal life in Down syndrome starts with normal neuronal density but impaired dendritic spines and synaptosomal structure. J Neural Transm Suppl 61: 59-70.
50. Yabut O., Domogauer J, D'Arcangelo G. 2010. Dyrk1A overexpression inhibits proliferation and induces premature neuronal differentiation of neural progenitor cells. J Neurosci 30: 4004-4014.
51. Yoshida A., Yamaguchi Y, Nonomura K, Kawakami K, Takahashi Y, Miura M. 2010. Simultaneous expression of different transgenes in neurons and glia by combining in utero electroporation with the Tol2 transposon-mediated gene transfer system. Genes Cells 15: 501-512.